A new chemotherapeutic regimen for advanced unresectable hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 50, Issue 53, 2003, Pages 1598-1602

  Seki, Shuichi ^a   Yamada, Takao ^a   Kawakita, Nobuyoshi ^a   Masuichi, Hideo ^a   Kitada, Takuya ^a   Sakaguchi, Hiroki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Arterial infusion; Cisplatin; Doxorubicin; UFT

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; TEGAFUR; URACIL;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CATHETER; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE INFECTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG INTOXICATION; FEMALE; FOLLOW UP; HUMAN; INJECTION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LYMPH NODE METASTASIS; LYMPHEDEMA; MALE; NEPHROTOXICITY; PORTAL VEIN; PRIORITY JOURNAL; SEPTICEMIA; TREATMENT OUTCOME; TUMOR THROMBUS;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 0141540368     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Okuda K: Early recognition of hepatocellular carcinoma. Hepatology 1986; 6:729-738.
2. Okuda K: Primary liver cancer in Japan. Cancer (Phila.) 1980; 45:2663-2672.
3. The Liver Cancer Study Group of Japan: Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment. Ann Surg 1990; 211:277-287.
4. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148:397-401.
5. Shiina S, Tagawa K, Unuma T, Terano A: Percutaneous ethanol injection therapy for treatment of hepatocellular carcinoma. Am J Roentgenol 1990; 154:947-951.
6. Sato M, Watanabe M, Nakarawa T, Ito T, Shiro T, Kunieda K, Kimura S, et al: Microwave coagulation therapy for hepatocellular carcinoma. Gastroenterology 1996; 110:1507-1514.
7. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer (Phila.) 1985; 56:918-928.
8. Calcly B: Natural history of primary and secondary tumors of the liver. Semin Oncol 1983; 10:127-134.
9. Ando E, Yamashita F, Tanaka M, Tanikawa K: A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer (Phila.) 1997; 79:1890-1896.
10. Fujii S, Kitano S, Ikenaka K, Shirasaka T: Effect of coadministration of uracil or cytocine on the antitumor activity of clinical doses of 1-92-tetrahydrofuryl)-5-fluorouracil in rodents. Jpn J Cancer Res (Gann) 1979; 70:209-214.
11. The Liver Cancer Study Group of Japan: In: The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Tokyo: Kanehara Shuppan Co., 1987; p. 18.
12. Nakamura K, Takashima S, Takada K, Fujimoto K, Kaminou T, Nakatsuka H, et al: Clinical evaluation of intermittent arterial infusion chemotherapy with an implanted reservoir for hepatocellular carcinoma. Cancer Chemother Pharmacol 1992; 31:S93-98.
13. Kajanti M, Pyrhonen S, Mantyla M, Rissanen P: Intra-arterial and intravenous use of 4′ epi-doxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. Am J Clin Oncol 1992; 15:37-40.
14. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kiriyama S et al: The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995; 52:295-299.
15. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, Carrasco H, et al: Hepatic arterial infusion of floxuridine, leukovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 1994; 12:1204-1211.
16. Shirasaki T, Shimamoto Y, Oshimo H, Saito H, Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32:167-172.
17. Schabel FM, Jr, Trader MW, Laster WR, Jr, Corbett TH, Griswold DP, Jr: cis-Dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63:1459-1473.
18. Drewinko B, Yang LY: Cellular basis for the inefficacy of 5-FU in human colon carcinoma. Cancer Treat Rep 1985; 69:1391-1398.
19. Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22:333-338.